Executive Summary .........5
United Arab Emirates Pharmaceuticals And Healthcare Industry SWOT ............................................................................................................. 6
United Arab Emirates Political SWOT .................................. 8
United Arab Emirates Economic SWOT ................................ 9
United Arab Emirates Business Environment SWOT........... 10
Pharmaceutical Business Environment Ratings ..............................................11
Table: Middle East And Africa Pharmaceutical Business Environment Ratings ................................................................................................. 11
Limits To Potential Returns ................................................. 11
Risks To Realisation Of Returns .......................................... 12
Market Summary ............13
Regulatory Environment ..........................................15
Recent Regulatory Developments ........................................ 15
Pharmaceutical Advertising................................................. 17
Intellectual Property Regime ............................................... 17
Counterfeit Medicines.......................................................... 18
Pricing And Reimbursement Regime.................................... 19
Table: Profit Margins For Medicines In The UAE .............. 20
Price Cuts ............................................................................ 20
Recent Pricing And Reimbursement Developments ............. 21
Regional Harmonisation...................................................... 23
Industry Trends And Developments .......................................25
Epidemiology....................................................................... 25
Healthcare Sector ................................................................ 26
Recent Healthcare Sector Developments ............................. 28
Health Insurance ................................................................. 29
Table: DHA Healthcarre System Implementation Timeline . 31
Expatriate Worker Insurance............................................... 32
Table: National Health Insurance Company - Available 32
Health Insurance Industry Developments ............................ 33
Health Tourism.................................................................... 34
Prescribing Practices .......................................................... 35
Domestic Pharmaceutical Sector......................................... 35
Foreign Companies.............................................................. 37
Company Developments....................................................... 37
Pharmaceutical Distribution and Retail .............................. 38
Recent Developments in Pharmaceutical Distribution and Retail ....................................................................................................................... 39
Research And Development ................................................. 40
DuBiotech............................................................................ 41
Table: Incentives For Companies To Move To DuBiotech .. 41
Complementary and Traditional Medicine .......................... 42
Medical Devices................................................................... 43
Table: The UAE's Medical Device Market, 2006-2012 (US$bn unless otherwise stated).................................................................................... 46
Recent Developments In The Medical Devices Market ........ 46
Industry Forecast Scenario ..............................................................47
Overall Market Forecast...................................................... 47
Table: Drug Expenditure And Prescription Market Indicators, 2006-2012 (AEDmn unless otherwise stated).................................................... 48
Key Growth Factors - Industry............................................ 49
Key Growth Factors - Industry............................................ 49
Table: Health Expenditure Trends, 2006-2012.................... 50
Macroeconomic Scenario .................................................... 51
Table: United Arab Emirates - Economic Activity............... 53
Patented Market Forecasts .................................................. 54
Table: Patented Drug Market Trends, 2006-2012 (US$bn unless otherwise stated)............................................................................................ 55
Generics Market Forecast ................................................... 56
Table: Generics And Patented Drug Market Indicators, 2006-2012.................................................................................................................... 56
OTC Market Forecast.......................................................... 57
Table: OTC Drug Market Trends (AEDmn unless otherwise stated) ................................................................................................................... 58
-Imports/Exports Forecasts.................................................. 59
-Imports/Exports Forecasts.................................................. 59
Table: Pharmaceutical Import/Export Trends (US$mn) ...... 60
Other Healthcare Forecasts................................................. 61
Table: Other Healthcare Data, 2006-2012.......................... 61
Key Risks To BMI's Forecast Scenario................................ 62
Competitive Landscape...........................................63
Table: Key Players In The UAE's Pharmaceutical Market, 2007........................................................................................................................ 63
Company Profiles...........64
Leading Foreign Companies..................................................... 64
GlaxoSmithKline.................................................................. 64
Pfizer ................................................................................... 66
Novartis ............................................................................... 68
Johnson & Johnson (J&J) ................................................... 71
Sanofi-Aventis...................................................................... 73
Abbott Laboratories............................................................. 74
Merck & Co ......................................................................... 76
Indigenous Manufacturers ........................................................ 78
Gulf Pharmaceutical Industries (Julphar) ........................... 78
Globalpharma...................................................................... 82
Modern Pharmaceutical Company (MPC) .......................... 84
NeoPharma.......................................................................... 85
BMI Forecast Modelling...........................................87
How We Generate Our Pharmaceutical Industry Forecasts ..... 87
Pharmaceutical Business Environment Ratings Methodology .. 87
Ratings Overview................................................................. 88
Table: Pharmaceutical Business Environment Indicators ... 89
Weighting............................................................................. 90
Table: Weighting Of Components........................................ 90
Sources ..................................................................................... 90